Enanta Pharmaceuticals Inc

NASDAQ:ENTA   3:59:55 PM EDT
41.33
-0.67 (-1.60%)
Products

Enanta Pharma Reports Positive Data From Phase 1B Study Of EDP-514, A Hepatitis B Virus Core Inhibitor

Published: 06/22/2021 20:11 GMT
Enanta Pharmaceuticals Inc (ENTA) - Enanta Pharmaceuticals Reports Positive Data From Phase 1b Study of Edp-514, a Hepatitis B Virus (hbv) Core Inhibitor, in Viremic Chronic Hbv Patients.
Enanta Pharmaceuticals Inc - Edp-514 Was Safe and Well-tolerated With Pharmacokinetics Supportive of Once-daily, Oral Dosing.
Enanta Pharmaceuticals Inc - Patients Dosed With 400 Mg Edp-514 Showed a Mean Reduction of 3.3 Logs in Hbv Dna.
Enanta Pharmaceuticals Inc - Positive 28-day Data From First Two Edp-514 Dose Cohorts: 200 Mg and 400 Mg.
Enanta Pharmaceuticals Inc - As Expected, No Clinically Significant Changes in Levels of Hbsag, Hbeag, Or Hbcrag Were Observed.